Revakinagene taroretcel
Revakinagene taroretcel, sold under the brand name Encelto, is an allogeneic encapsulated cell-based gene therapy used for the treatment of macular telangiectasia type 2. Revakinagene taroretcel is administered into the recipient's eye during a single surgical procedure.
Revakinagene taroretcel works by expressing recombinant human ciliary neurotrophic factor, which is a factor that may promote the survival and maintenance of the macular photoreceptors.
Revakinagene taroretcel was approved for medical use in the United States in March 2025.
Medical uses
Revakinagene taroretcel is indicated for the treatment of adults with idiopathic macular telangiectasia type 2.Macular telangiectasia type 2 is a rare progressive disease of the macula, leading to degeneration of the photoreceptors which are specialized light-detecting cells in the back of the eye.